Research programme: epigenetic therapeutics - Constellation Pharmaceuticals

Drug Profile

Research programme: epigenetic therapeutics - Constellation Pharmaceuticals

Alternative Names: CPI-169; CPI-203; CPI-232; CPI-267203; CPI-360; EZH2 inhibitors - Constellation Pharmaceuticals; Inhibitors of BET family of bromodomain-containing proteins - Constellation Pharmaceuticals; Inhibitors of histone methyltransferase - Constellation Pharmaceuticals

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Constellation Pharmaceuticals
  • Developer Constellation Pharmaceuticals; Genentech; University of Pittsburgh
  • Class Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Histone deacetylase inhibitors; Histone methyltransferase inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours
  • No development reported Cancer; Cystic fibrosis; Haematological malignancies; Immunological disorders; Inflammation; Multiple myeloma

Most Recent Events

  • 09 Apr 2018 Preclinical trials in Solid tumours in USA (unspecified route) before April 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top